EGFR mutation-related tumors

Clinical trials for EGFR mutation-related tumors explained in plain language.

Never miss a new study

Get alerted when new EGFR mutation-related tumors trials appear

Sign up with your email to follow new studies for EGFR mutation-related tumors, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Completed 1 Terminated 1

New combo therapy shows promise for Hard-to-Treat lung cancer

Disease control Completed

This early-phase study tested a new drug called ONO-7475 combined with the standard targeted therapy osimertinib in 78 people with advanced EGFR-mutated non-small cell lung cancer. The goal was to see if the combination is safe and tolerable. Participants had stage IIIB, IIIC, IV…

Matched conditions: EGFR MUTATION-RELATED TUMORS

Phase 1 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control

Last updated Jun 27, 2026 11:00 UTC

EGFR mutation-related tumors

Get alerted when new EGFR mutation-related tumors trials appear

New combo therapy shows promise for Hard-to-Treat lung cancer